Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

The Yobe State Government has disclosed that over 1,000 blood and urine samples, along with 300 samples of soil, water, fish, vegetables, and other food items, have been collected in Bade as part of ...

Having high blood pressure—something that roughly half of Americans are living with—is a big deal. It increases the risk for ...

ZAKIRA M. YASEEN ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

MELAKA, Feb 18 (Bernama) -- The implementation of the free influenza vaccination programme for senior citizens, aged 60 and ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Living kidney donors with discordant kidney function measures had lower eGFR after donation and a higher risk for eGFR counts ...

Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...